All Oncology News

Randy F. Sweis, MD, discusses recent progress and next steps in the prostate cancer paradigm.

Michael Link, MD, a 2018 Giant of Cancer Care® in Pediatric Oncology, discusses the exciting progress being made for various pediatric tumors.

Krishnansu S. Tewari, MD, discusses the exploration of cemiplimab and the promise of immunotherapy in cervical cancer.

The FDA has approved the next-generation sequencing assay clonoSEQ as a test for minimal residual disease (MRD) in patients with acute lymphoblastic leukemia or multiple myeloma.

Yelena Y. Janjigian, MD, discusses the reality of biosimilars entering the US market and how oncologists should approach discussing these agents with their patients.

The FDA has granted the PARP inhibitor rucaparib a breakthrough therapy designation for single-agent use in adult patients with BRCA1/2-positive metastatic castration-resistant prostate cancer following at least 1 androgen receptor–directed therapy and taxane-based chemotherapy.

Physicians at the John Theurer Cancer Center at Hackensack Meridian Health Hackensack University Medical Center have enrolled the first two patients nationwide in an international phase II clinical trial of Kazia Therapeutics's novel therapy, GDC-0084, for glioblastoma.

Combining brentuximab vedotin with frontline chemotherapy led to a statistically significant improvement in progression-free and overall survival in patients with CD30-expressing peripheral T-cell lymphoma, according to topline results from the phase III ECHELON-2 trial.

Immunotherapy pioneers James P. Allison, PhD, and Tasuku Honjo, MD, PhD, have won the 2018 Nobel Prize in Physiology or Medicine for their research that eventually led to the use of immune checkpoint inhibitors to treat cancer.

Javier A. Pinilla-Ibarz, MD, PhD, discusses updates in the treatment of patients with chronic lymphocytic leukemia.

The FDA has approved a once-weekly dosing option of carfilzomib to use in combination with dexamethasone for patients with relapsed/refractory multiple myeloma.

The FDA has approved the PD-1 inhibitor cemiplimab (Libtayo) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC who are not candidates for curative surgery or curative radiation.

Women with operable HER2-positive breast cancer had similar long-term survival outcomes with either concurrent or sequential chemotherapy in the neoadjuvant setting, according to newly published results from the phase III ACOSOG Z1041 trial.

The FDA has approved dacomitinib (Vizimpro) for the frontline treatment of patients with metastatic non–small cell lung cancer with EGFR exon 19 deletion or exon 21 L858R substitution mutations.

Radhakrishnan Ramchandren, MD, discusses the treatment landscape in Hodgkin and T-cell lymphoma and the results of the North American subgroup analysis of the ECHELON-1 trial.

Geoffrey R. Oxnard, MD, discusses the promise of genome-wide sequencing in cell-free DNA.

Joseph Uberti, MD, PhD, discusses the risk and benefit of a bone marrow transplant for patients with myelodysplastic syndrome.

Jay Yang, MD, explains that drug development is not as simple as identifying a molecular target and matching inhibitor.

Jeffrey S. Weber, MD, PhD, discusses the promise of nivolumab in this setting and a general overview of the melanoma treatment landscape.

Joshua J. Meeks, MD, PhD, discusses the current understanding of genomics in bladder cancer.

Feinstein Institute for Medical Research Assistant Professor Catherine Benedict, PhD, has been awarded a 5-year, $693,000 grant from the National Institutes of Health to develop and test a digital health platform to help young female cancer survivors evaluate their options for having children, make decisions and plan for the future.

Urologists at Northwell Health’s Smith Institute for Urology recently started offering a new biopsy procedure which samples tissue from the prostate to potentially detect cancer – and eliminates the risk of infection.

Lurbinectedin plus doxorubicin demonstrated significant clinical activity as a second-line therapy for patients with small cell lung cancer, especially when excluding refractory patients.

Ongoing analyses suggest enhanced clinical benefit is derived from the combined use of entinostat and pembrolizumab in a subgroup of patients with PD-1/PD-L1–refractory non–small cell lung cancer who have high levels of peripheral blood monocytes.

Rami S. Komrokji, MD, reflects on the diverse acute myeloid leukemia treatment landscape and touches on the prognostic importance of biomarkers.

The addition of atezolizumab to standard carboplatin and etoposide in the frontline setting significantly prolonged survival in patients with extensive-stage small cell lung cancer compared with the chemotherapy regimen alone.

Brigatinib reduced the risk of disease progression or death by more than 50% compared to crizotinib in adult patients with ALK-positive, locally advanced or metastatic NSCLC.

Walter M. Stadler, MD, gives an overview of the current prostate cancer landscape and discussed future directions.

Durvalumab induced a clinically meaningful improvement in overall survival compared with placebo in patients with stage III, unresectable non–small cell lung cancer who have not progressed following chemoradiotherapy.

The addition of atezolizumab to carboplatin/cisplatin in the first-line setting and to pemetrexed as maintenance therapy significantly improved progression free survival in patients with stage IV nonsquamous NSCLC.